Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005;117(2):294–9.
Article
CAS
Google Scholar
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.
Article
Google Scholar
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.
Article
Google Scholar
Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004;100(12):2613–21.
Article
CAS
Google Scholar
Price N. Bisphosphonates to prevent skeletal morbidity in patients with lung cancer with bone metastases. Clin Lung Cancer. 2004;5(5):267–9.
Article
CAS
Google Scholar
Delea TE, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M, Oster G. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol. 2006;1(6):571–6.
Article
Google Scholar
Langer C, Hirsh V. Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates. Lung cancer (Amsterdam, Netherlands). 2010;67(1):4–11.
Article
Google Scholar
Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer. 1998;77(2):336–40.
Article
CAS
Google Scholar
Ibrahim T, Mercatali L, Amadori D. Bone and cancer: the osteoncology. Clin Cases Miner Bone Metab. 2013;10(2):121–3.
PubMed
PubMed Central
Google Scholar
Lopez-Olivo MA, Shah NA, Pratt G, Risser JM, Symanski E, Suarez-Almazor ME. Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis. Support Care Cancer. 2012;20(11):2985–98.
Article
Google Scholar
Zhang L, Gong Z. Clinical characteristics and prognostic factors in bone metastases from lung Cancer. Med Sci Monit. 2017;23:4087–94.
Article
Google Scholar
Chambard L, Girard N, Ollier E, Rousseau JC, Duboeuf F, Carlier MC, Brevet M, Szulc P, Pialat JB, Wegrzyn J, et al. Bone, muscle, and metabolic parameters predict survival in patients with synchronous bone metastases from lung cancers. Bone. 2018;108:202–9.
Article
CAS
Google Scholar
Sugiura H, Yamada K, Sugiura T, Hida T, Mitsudomi T. Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res. 2008;466(3):729–36.
Article
Google Scholar
Tsuya A, Kurata T, Tamura K, Fukuoka M. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer (Amsterdam, Netherlands). 2007;57(2):229–32.
Article
Google Scholar
Silva GT, Bergmann A, Thuler LC. Incidence, associated factors, and survival in metastatic spinal cord compression secondary to lung cancer. Spine J. 2015;15(6):1263–9.
Article
Google Scholar
Batson OV. The function of the vertebral veins and their role in the spread of metastases. Ann Surg. 1940;112(1):138–49.
Article
CAS
Google Scholar
Kahn D, Weiner GJ, Ben-Haim S, Ponto LL, Madsen MT, Bushnell DL, Watkins GL, Argenyi EA, Hichwa RD. Positron emission tomographic measurement of bone marrow blood flow to the pelvis and lumbar vertebrae in young normal adults. Blood. 1994;83(4):958–63.
CAS
PubMed
Google Scholar
Coleman RE. Management of bone metastases. Oncologist. 2000;5(6):463–70.
Article
CAS
Google Scholar
Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125–32.
Article
CAS
Google Scholar
Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, Solal-Celigny P, Rodriguez G, Krzakowski M, Mehta ND, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol. 2012;7(12):1823–9.
Article
CAS
Google Scholar
Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–51.
Article
CAS
Google Scholar
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50.
Article
CAS
Google Scholar
Satoh H, Ishikawa H, Yamashita YT, Naito T, Takahashi H, Kamma H, Ohtsuka M, Hasegawa S. Analysis of long-term survivors after platinum containing chemotherapy in advanced non-small cell lung cancer. Anticancer Res. 1998;18(2b):1295–8.
CAS
PubMed
Google Scholar
Satoh H, Ishikawa H, Ohara G, Kagohashi K, Kurishima K, Ohtsuka M, Hizawa N. Long-term survivors after chemotherapy in advanced non-small cell lung cancer. Anticancer Res. 2007;27(6c):4457–60.
PubMed
Google Scholar
Le Chevalier T, Brisgand D, Soria JC, Douillard JY, Pujol JL, Ruffie P, Aberola V, Cigolari S. Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer. Oncologist. 2001;6(Suppl 1):8–11.
Article
Google Scholar
Kojima A, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Oshita F, Miya T, Okamoto H, Kondo H, et al. Analysis of three-year survivors among patients with advanced inoperable non-small cell lung cancer. Jpn J Clin Oncol. 1991;21(4):276–81.
CAS
PubMed
Google Scholar
Caglayan B, Fidan A, Salepci B, Kiral N, Torun E, Salepci T, Mayadagli A. Effects of prognostic factors and treatment on survival in advanced non-small cell lung cancer. Tuberkuloz ve toraks. 2004;52(4):323–32.
PubMed
Google Scholar
Niewald M, Tkocz HJ, Abel U, Scheib T, Walter K, Nieder C, Schnabel K, Berberich W, Kubale R, Fuchs M. Rapid course radiation therapy vs. more standard treatment: a randomized trial for bone metastases. Int J Radiat Oncol Biol Phys. 1996;36(5):1085–9.
Article
CAS
Google Scholar
Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases: final results of the study by the radiation therapy oncology group. Cancer. 1982;50(5):893–9.
Article
CAS
Google Scholar
Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20 Pt 2):6243s–9s.
Article
Google Scholar
van der Linden YM, Steenland E, van Houwelingen HC, Post WJ, Oei B, Marijnen CA, Leer JW. Patients with a favourable prognosis are equally palliated with single and multiple fraction radiotherapy: results on survival in the Dutch bone metastasis study. Radiother Oncol. 2006;78(3):245–53.
Article
Google Scholar
Arcangeli G, Giovinazzo G, Saracino B, D'Angelo L, Giannarelli D, Arcangeli G, Micheli A. Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response duration. Int J Radiat Oncol Biol Phys. 1998;42(5):1119–26.
Article
CAS
Google Scholar
Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(8 Suppl):1588–94.
Article
CAS
Google Scholar
Yoshino I, Yohena T, Kitajima M, Ushijima C, Nishioka K, Ichinose Y, Sugimachi K. Survival of non-small cell lung cancer patients with postoperative recurrence at distant organs. Ann Thorac Cardiovasc Surg. 2001;7(4):204–9.
CAS
PubMed
Google Scholar
Oh Y, Taylor S, Bekele BN, Debnam JM, Allen PK, Suki D, Sawaya R, Komaki R, Stewart DJ, Karp DD. Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases. Cancer. 2009;115(13):2930–8.
Article
Google Scholar
Yano T, Haro A, Yoshida T, Morodomi Y, Ito K, Shikada Y, Shoji F, Maruyama R, Maehara Y. Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer. J Surg Oncol. 2010;102(7):852–5.
Article
Google Scholar
Di Lascio S, Pagani O. Oligometastatic breast cancer: a shift from palliative to potentially curative treatment? Breast care (Basel, Switzerland). 2014;9(1):7–14.
Article
Google Scholar
van der Linden YM, Kroon HM, Dijkstra SP, Lok JJ, Noordijk EM, Leer JW, Marijnen CA. Simple radiographic parameter predicts fracturing in metastatic femoral bone lesions: results from a randomised trial. Radiother Oncol. 2003;69(1):21–31.
Article
Google Scholar
Willeumier JJ, van der Linden YM, van de Sande MAJ, Dijkstra PDS. Treatment of pathological fractures of the long bones. EFORT Open Rev. 2016;1(5):136–45.
Article
Google Scholar